A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05251883

Enrollment

200

Registered

2022-02-23

Start date

2022-01-01

Completion date

2026-12-31

Last updated

2023-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

multi-omics, ovarian cancer

Brief summary

As one of the most common malignant tumors in women, the incidence of ovarian cancer is expected to increase year by year. Due to its lack of typical symptoms and effective screening methods, and the characteristics of implantation and distant metastasis, more than 70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study, the investigators will collect large samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer, and explore the molecular mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the investigators will design and establish a database of metastatic ovarian cancer, integrate multiple omics, imaging, pathology, and clinical information to study their potential relevance, and analyze the relationship between various omics, imaging, pathology, and prognosis, establish ovaries Cancer prediction model.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. female, ≥18 years old; 2. diagnosed as ovarian cancer by imaging and pathology; 3. did not receive any anti-tumor drug treatment before surgery in the gynecology clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University; 4. received ovarian cancer surgery and Follow-up treatment; 5. Patients voluntarily participate in the research of this subject, have good compliance, and can complete the enrollment by the requirements of the trial; 6. Sign informed consent and agree to the collection and use of their data.

Exclusion criteria

1. Patients who have received other anti-tumor treatments or received tumor surgery before enrollment; 2. Patients with malignant tumors in other parts; 3. Patients with uncontrollable neurological, psychiatric, or mental disorders; 4. Poor compliance and inability to Cooperate and describe treatment responders.

Design outcomes

Primary

Measure	Time frame
Progression-Free-Survival	The sample will be tested immediately after they are taken from patients and the statistical analysis will be taken through study completion, an average of 3 year

Countries

China

Contacts

Primary ContactHuaiwu Lu, Study Director

luhuaiwu@mail.sysu.edu.cn+86 18688395806

Outcome results